No Data
Jinyao Pharmaceuticals Obtains Drug Registration for Opioid Overdose Drug
Tianjin Tianyao Pharmaceuticals (600488.SH): The subsidiary has obtained the pharmaceutical registration certificate.
On March 17, Longhu announced that Tianjin Tianyao Pharmaceuticals (600488.SH) reported that its subsidiary Hubei Tianyao Pharmaceuticals Co., Ltd. (referred to as "Hubei Tianyao") has received the drug registration certificate for Naloxone Hydrochloride Injection (referred to as "the pharmaceutical" or "this product") issued by the National Medical Products Administration. Naloxone Hydrochloride Injection is an opioid receptor antagonist.
Tianjin Tianyao Pharmaceuticals (600488.SH): Passed the USA FDA cGMP on-site inspection.
On March 12th, Gelonghui reported that Tianjin Tianyao Pharmaceuticals (600488.SH) announced that from December 9th to December 13th, 2024, it underwent a cGMP (current Good Manufacturing Practice) inspection by the USA Food and Drug Administration (FDA). Recently, the company received the Establishment Inspection Report (EIR) issued by the FDA, indicating that the company's manufacturing site has passed this cGMP inspection.
Tianjin Tianyao Pharmaceuticals Secures Food Production License for Amino Acids
Tianjin Tianyao Pharmaceuticals (600488.SH) has obtained the GMP certification issued by the Brazilian Health Regulatory Agency.
Tianjin Tianyao Pharmaceuticals (600488.SH) announced that the company will accept applications from October 21 to 25, 2024...
Jinyao Pharmaceutical Gets Registration Certificate for Formoterol Fumarate Inhalation Solution
Earnings Not Telling The Story For Tianjin Tianyao Pharmaceuticals Co., Ltd. (SHSE:600488)
